Alzheimers Drug Discovery Foundation revealed that the amyloid-clearing drug lecanemab will be a positive action in the treatment of Alzheimers disease based upon study results provided at the 15th Clinical Trials on Alzheimers Disease (CTAD) conference and published in The New England Journal of Medicine.
Favorable results from new amyloid-clearing drug represent a beginning point for Alzheimers treatment, while combination treatment remains the holy grail.
Amyloid-clearing drug lecanemab will be a favorable action in the treatment of Alzheimers illness based upon study results provided at the 15th Clinical Trials on Alzheimers Disease (CTAD) conference and released in The New England Journal of Medicine. Lecanemab is poised for FDA approval early next year. Alzheimers is an intricate disease with numerous underlying causes connected to the biology of aging, therefore the Alzheimers Drug Discovery Foundation (ADDF) has actually long held that a combination drug approach is required.
” Todays results show that lecanemab slows cognitive decrease, which is welcome news for the countless clients and families living with Alzheimers,” said Dr. Howard Fillit, Co-Founder and Chief Science Officer at the ADDF. “But this is just a start to stopping Alzheimers in its tracks. We have a great deal of ground to cover to obtain from the 27% slowing lecanemab offers to our goal of slowing cognitive decline by 100%.”.
Amyloid-clearing drug lecanemab will be a positive action in the treatment of Alzheimers illness based on research study results provided at the 15th Clinical Trials on Alzheimers Disease (CTAD) conference and published in The New England Journal of Medicine. Alzheimers is a complex illness with multiple underlying causes connected to the biology of aging, for that reason the Alzheimers Drug Discovery Foundation (ADDF) has long held that a mix drug method is needed.
” Todays news is motivating for everybody who has actually worked on lecanemab and for those of us who have invested years tackling Alzheimers by enhancing scientific trial designs,” stated Dr. Fillit.
Amyloid-clearing drugs are one part of the service, however there remains a pushing requirement to develop a brand-new generation of drugs targeting all elements of the biology of aging that can be combined to attend to the full selection of underlying pathologies that add to the disease. New and emerging easy-to-use diagnostic tools like those supported by the ADDFs Diagnostics Accelerator can help identify the specific underlying causes of everyones Alzheimers, allowing accuracy treatment methods and enhancing clinical trials.
” Unique drug combinations matched to each patients underlying pathologies is the response, and our finest wish to offer clients long-lasting remedy for this insidious and progressive disease,” stated Dr. Fillit.
Todays Alzheimers drug pipeline is more robust than ever, with 75% of drugs presently in medical trials focused on novel targets beyond amyloid and tau according to a current report.
” Todays news is encouraging for everyone who has dealt with lecanemab and for those people who have spent years taking on Alzheimers by improving scientific trial designs,” stated Dr. Fillit. “But much more, this is evidence that our research is paying off. It gives us a clear vision of a day soon when treatments will permit clients to keep their self-reliance not just for months or weeks more, but for years more and maybe for their life times.
Reference: “Lecanemab in Early Alzheimers Disease” by Christopher H. van Dyck, M.D., Chad J. Swanson, Ph.D., Paul Aisen, M.D., Randall J. Bateman, M.D., Christopher Chen, B.M., B.Ch., Michelle Gee, Ph.D., Michio Kanekiyo, M.S., David Li, Ph.D., Larisa Reyderman, Ph.D., Sharon Cohen, M.D., Lutz Froelich, M.D., Ph.D., Sadao Katayama, M.D., Marwan Sabbagh, M.D., Bruno Vellas, M.D., David Watson, Psy.D., Shobha Dhadda, Ph.D., Michael Irizarry, M.D., Lynn D. Kramer, M.D., and Takeshi Iwatsubo, M.D., 29 November 2022, The New England Journal of Medicine.DOI: 10.1056/ NEJMoa2212948.
